Skip to main content

Advertisement

SpringerLink
Log in

Tuberculosis and HIV infection

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

We review important new recommendations on the treatment and prophylaxis of tuberculosis in HIV-infected individuals. Large-scale studies and expert consensus panels have both concluded that shorter courses and intermittent antituberculous regimens are adequate for the treatment of dually infected individuals. Also, the substitution of rifabutin for rifampin for the treatment and prophylaxis of tuberculosis has been shown to be advantageous, providing equivalent efficacy to regimens containing rifampin, and fewer drug interactions with antiretroviral medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998, 47(RR20):1–51. A comprehensive review of the world literature and expert consensus about the new recommendations for treatment and prophylaxis of tuberculosis in HIV-infected patients.

  2. Kunin CM: Antimicrobial activity of rifabutin. Clin Infect Dis 1996, 22:S3-S14.

    PubMed  CAS  Google Scholar 

  3. Schwander S, Rusch-Gerdes S, Mateega A, et al.: A pilot study of antituberculous combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis: a single blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis 1995, 76:210–218. This study is the only one that compared rifabutin and RIF for the treatment of tuberculosis in HIV-infected patients and showed that both were similarly effective and safe.

    Article  PubMed  CAS  Google Scholar 

  4. McGregor MM, Olliaro P, Wolmarans L, et al.: Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996, 154:1462–1467. This study included 298 patients from South Africa and demonstrated that rifabutin’s efficacy and tolerability is comparable to that of RIF.

    PubMed  CAS  Google Scholar 

  5. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P: Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuber Lung Dis 1994, 75:341–347.

    Article  PubMed  CAS  Google Scholar 

  6. El-Sadr W, Perlman D, Matts J, et al.: Evaluation of an intensive intermittent induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998, 26:1148–1158. This study included 227 US patients dually infected, and showed that a largely intermittent four-drug regimen for 6 or 9 months is associated with low failure and relapse rates.

    PubMed  CAS  Google Scholar 

  7. Mwinga A, Godfrey-Fausset P, Quigley M, et al.: Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998, 12:2447–2457. This double-blind, placebo-controlled trial included 1053 subjects from Zambia and demonstrated that either twice weekly INH for 6 months or a combination of RIF and PZA for 2 months reduced the incidence of tuberculosis infection.

    Article  PubMed  CAS  Google Scholar 

  8. Halsey N, Coberly J, Desormeaux J, et al.: Randomized trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998, 351:786–792. This prospective study of 784 dually infected patients showed that twice weekly INH preventive therapy or rifampicin plus PZA provided similar overall protection against tuberculosis in dually infected patients.

    Article  PubMed  CAS  Google Scholar 

  9. Gordin F, Chaisson R, Matts J, et al.: A randomized trial of 2 months of rifampin (RIF) and pyrazinamide (PZA) versus 12 months of isoniazid (INH) for the prevention of tuberculosis (TB) in HIV-positive (+), PPD+ patients (PTS) [abstract]. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL; 1998. This multicenter study included almost 1600 HIV-infected patients and also demonstrated the effectiveness of short-course RIF and PZA for prophylaxis of tuberculosis in purified protein derivative-positive individuals.

Download references

Author information

Authors and Affiliations

  1. AIDS Program, Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, 135 College Street, Suite 323, 06520, New Haven, CT, USA

    Martha I. Buitrago MD & Gerald Friedland MD

Authors
  1. Martha I. Buitrago MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerald Friedland MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buitrago, M.I., Friedland, G. Tuberculosis and HIV infection. Curr Infect Dis Rep 1, 105–109 (1999). https://doi.org/10.1007/s11908-999-0017-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-999-0017-3

Keywords

Search

Navigation